Your browser doesn't support javascript.
loading
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.
Yang, Kaiwei; Hu, Hailong; Wu, Junlong; Wang, Huina; Guo, Zhaoxia; Yu, Wei; Yao, Lin; Ding, Feng; Zhou, Tao; Wang, Wang; Wang, Yunkai; Liu, Lei; Guo, Jing; Zhu, Shuaipeng; Zhang, Xinhao; Cao, Shanbo; Lou, Feng; Niu, Yuanjie; Ye, Dingwei; He, Zhisong.
Afiliación
  • Yang K; Department of Urology, Peking University First Hospital, No. 8 Xishiku Dajie, Xicheng District, Beijing, 100034, People's Republic of China.
  • Hu H; Department of Urology, The Second Affiliated Hospital of Tianjin Medical University, Tianjin, 300211, People's Republic of China.
  • Wu J; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
  • Wang H; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Guo Z; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Yu W; Department of Urology, Peking University First Hospital, No. 8 Xishiku Dajie, Xicheng District, Beijing, 100034, People's Republic of China.
  • Yao L; Department of Urology, Peking University First Hospital, No. 8 Xishiku Dajie, Xicheng District, Beijing, 100034, People's Republic of China.
  • Ding F; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Zhou T; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Wang W; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Wang Y; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Liu L; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Guo J; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Zhu S; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Zhang X; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China.
  • Cao S; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China. shanbocao@acornmed.com.
  • Lou F; Acornmed Biotechnology Co., Ltd, Beijing, 100176, People's Republic of China. fenglou@acornmed.com.
  • Niu Y; Department of Urology, The Second Affiliated Hospital of Tianjin Medical University, Tianjin, 300211, People's Republic of China. niuyuanjie9317@163.com.
  • Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China. dwyeli@163.com.
  • He Z; Department of Urology, Peking University First Hospital, No. 8 Xishiku Dajie, Xicheng District, Beijing, 100034, People's Republic of China. wyj7074@sohu.com.
Mol Cancer ; 22(1): 25, 2023 02 04.
Article en En | MEDLINE | ID: mdl-36739413
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Carcinoma de Células Transicionales Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article